 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery
|
|
|
|
Phase III
|
|
|
|
ECOG-E2805
E2805, CALGB-E2805, SWOG-E2805, CAN-NCIC-E2805, NCT00326898
|
|
| |
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
|
|
|
|
Phase III
|
|
|
|
A6181109
NCT00375674
|
|
| |
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
|
|
|
|
Phase III
|
|
|
|
A6181114
NCT00428220
|
|
| |
Warm Ischemia or Cold Ischemia During Surgery in Treating Patients With Stage I Kidney Cancer
|
|
|
|
Phase III
|
|
|
|
CCCWFU-89108
CCCWFU 89108, NCT00743236
|
|
| |
Ixabepilone in Treating Patients With Renal Cell Carcinoma (Kidney Cancer)
|
|
|
|
Phase II
|
|
|
|
NCI-02-C-0130
CC-02-C-0130, NCI-3654, 3654, NCT00033670
|
|
| |
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Von Hippel-Lindau Disease and Kidney Cancer
|
|
|
|
Phase II
|
|
|
|
NCI-04-C-0238
6399, NCI-6399, NCT00089375
|
|
| |
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
|
|
|
|
Phase II
|
|
|
|
COG-AREN0321
AREN0321, NCT00335556
|
|
| |
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
|
|
|
|
Phase II
|
|
|
|
CINJ-3330
NCT00161187
|
|
| |
Vandetanib in Treating Patients With Von Hippel-Lindau Syndrome and Kidney Tumors
|
|
|
|
Phase II
|
|
|
|
NCI-08-C-0020
08-C-0020, NCI-P07148, NCT00566995
|
|
| |
A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
|
|
|
|
Phase II
|
|
|
|
MET111644
NCT00726323
|
|
